Fetal Blood Contains More Forever Chemicals Than Expected

Mount Sinai researchers recently uncovered 42 distinct per- and polyfluoroalkyl substances, known as PFAS, in newborn blood samples. Previous assessments of fetal exposure generally focused on a narrow subset of these synthetic compounds. The results suggest that the prenatal environment is saturated with a far wider variety of industrial chemicals than clinical guidelines now acknowledge. Initial tests typically look for PFOA and PFOS, two of the most well-documented members of the PFAS family. The Mount Sinai findings show that fetal PFAS exposure is broader than standard clinical screens have been built to detect. But the expanded methodology used by the Mount Sinai team revealed a chemical cocktail that includes dozens of newer, less-studied variants. These substances belong to a class of more than 10,000 chemicals used in products ranging from non-stick cookware to firefighting foam. Carbon-fluorine bonds provide these chemicals with their signature durability. This molecular structure is among the strongest in organic chemistry, preventing the substances from breaking down in the environment or the human body. Because they do not degrade, they accumulate in soil, water, and biological tissue over decades. Health experts often refer to them as forever chemicals due to this extreme persistence.

Mount Sinai Finds Wider PFAS Exposure

Researchers at the Mount Sinai Icahn School of Medicine used high-resolution mass spectrometry to identify the chemical signatures in the cord blood. This technique allows for the detection of substances without a pre-defined list of targets. Traditional testing methods only find what they are specifically programmed to look for. The study found that nearly all samples contained multiple PFAS compounds that are rarely tracked in public health surveys.

Exposure begins long before a child takes their first breath. PFAS molecules are small enough to pass through the placental barrier, which is intended to protect the developing fetus from harmful pathogens and toxins. The placenta appears to be highly permeable to these synthetic chains. Maternal blood carries the chemicals directly into the fetal circulatory system where they begin to accumulate in developing organs.

Evidence suggests that the concentration of these chemicals in fetal blood can sometimes match or exceed the levels found in the mother. For instance, certain short-chain PFAS variants appear to migrate across the placenta more efficiently than their long-chain predecessors. These newer versions were introduced by industry as safer alternatives to legacy chemicals. Yet the data indicates they are just as persistent and potentially more mobile within the human body.

This study shows that the number of PFAS chemicals newborns are exposed to is much higher than we thought, and we need to understand the health risks of these complex mixtures.

Epidemiological studies have linked PFAS exposure to a variety of adverse health outcomes. In particular, prenatal exposure is associated with lower birth weights and altered immune system development. Some researchers have documented a correlation between high PFAS levels in cord blood and a reduced response to childhood vaccinations. The chemicals appear to interfere with the signaling pathways that govern immune maturation.

Placenta Barrier Looks Less Protective

Drinking water remains the primary vector for PFAS entry into the human population. Industrial runoff and the use of aqueous film-forming foams at military bases have contaminated groundwater across the United States and Europe. Once ingested, these chemicals bind to proteins in the blood. They circulate through the liver and kidneys, but the body lacks an efficient mechanism to excrete them. They remain in the bloodstream for years.

Consumer products provide a secondary, more insidious route of exposure. Dust in homes often contains high concentrations of PFAS shed from stain-resistant carpets and water-repellent upholstery. Pregnant women inhale or ingest these particles during daily activities. The most direct pathway to the fetus remains the umbilical cord. The developing child acts as a biological sink for the mother's accumulated chemical burden.

The chemical industry has long maintained that modern PFAS variants do not pose a notable risk to human health. Trade groups argue that the concentrations found in most people are below the thresholds required to trigger biological damage. They emphasize that short-chain chemicals are eliminated from the body faster than legacy substances. They have resisted broad bans on the entire class of chemicals. Regulatory agencies like the EPA have recently moved to establish stricter limits on several PFAS compounds in drinking water. These new standards target six particular chemicals, including PFOA and PFOS. But the Mount Sinai findings highlight the limitations of a substance-by-substance regulatory approach. With thousands of variants in circulation, banning six chemicals does little to address the 42 PFAS compounds found in the newborn samples.

Regulators Face a Testing Gap

Current federal law in the United States does not require companies to prove a chemical is safe before it enters the market. Instead, the government must prove a substance is harmful before it can be restricted. This reactive structure has allowed the chemical industry to iterate through different PFAS versions whenever one comes under scrutiny. When the EPA pressured companies to phase out long-chain chemicals, they simply pivoted to shorter-chain versions with similar properties.

European regulators have proposed a more aggressive strategy. The European Chemicals Agency is now considering a plan to ban the entire class of PFAS chemicals as a group. The proposal is based on the precautionary principle, which suggests that if a class of chemicals is known to be persistent and potentially toxic, the entire group should be restricted. The U.S. continues to treat each molecule as a separate legal entity.

Manufacturers such as 3M and DuPont have faced billions of dollars in legal settlements over water contamination. These lawsuits often center on internal company documents showing the risks of PFAS decades before the public was informed. Despite these payouts, the production of various PFAS iterations continues globally. International trade allows products treated with these chemicals to enter markets even where their manufacture is restricted. Monitoring fetal exposure is complicated by the lack of standardized testing in neonatal care. Most hospitals do not screen cord blood for environmental toxins. Doctors typically only order toxicology screens if they suspect drug or alcohol use during pregnancy. As a result, the vast majority of parents remain unaware of the chemical load their children are carrying at birth.

Single-Chemical Rules Miss the Mixture

The study adds pressure for regulators to look beyond one chemical at a time. Fetal exposure appears to involve mixtures, and public-health rules built around single compounds may not match what researchers are seeing in newborn blood.